Atsuko Hachiya1, Mai Kubota1, Urara Shigemi1, Hirotaka Ode1, Yoshiyuki Yokomaku1, Karen A Kirby2,3, Stefan G Sarafianos2,3, Yasumasa Iwatani1,4. 1. Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan. 2. Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. 3. Children's Healthcare of Atlanta, Atlanta, GA, USA. 4. Department of AIDS Research, Nagoya University Graduate School of Medicine, Aichi, Japan.
Abstract
BACKGROUND: In vitro selection experiments identified viruses resistant to integrase strand transfer inhibitors (INSTIs) carrying mutations in the G-tract (six guanosines) of the 3'-polypurine tract (3'-PPT). A clinical study also reported that mutations in the 3'-PPT were observed in a patient receiving dolutegravir monotherapy. However, recombinant viruses with the 3'-PPT mutations that were found in the clinical study were recently shown to be susceptible to INSTIs. OBJECTIVES: To identify the specific mutation(s) in the G-tract of the 3'-PPT for acquiring INSTI resistance, we constructed infectious clones bearing single or multiple mutations and systematically characterized the susceptibility of these clones to both first- and second-generation INSTIs. METHODS: The infectious clones were tested for their infectivity and susceptibility to INSTIs in a single-cycle assay using TZM-bl cells. RESULTS: A single mutation of thymidine (T) at the fifth position (GGG GTG) in the G-tract of the 3'-PPT had no effect on INSTI resistance. A double mutation, cytidine (C) or 'T' at the second position and 'T' at the fifth position (GCG GTG and GTG GTG), increased resistance to INSTIs, with the appearance of a plateau in the maximal percentage inhibition (MPI) of the dose-response curves, consistent with a non-competitive mechanism of inhibition. CONCLUSIONS: Mutations at the second and fifth positions in the G-tract of the 3'-PPT may result in complex resistance mechanism(s), rather than simply affecting INSTI binding at the IN active site.
BACKGROUND: In vitro selection experiments identified viruses resistant to integrase strand transfer inhibitors (INSTIs) carrying mutations in the G-tract (six guanosines) of the 3'-polypurine tract (3'-PPT). A clinical study also reported that mutations in the 3'-PPT were observed in a patient receiving dolutegravir monotherapy. However, recombinant viruses with the 3'-PPT mutations that were found in the clinical study were recently shown to be susceptible to INSTIs. OBJECTIVES: To identify the specific mutation(s) in the G-tract of the 3'-PPT for acquiring INSTI resistance, we constructed infectious clones bearing single or multiple mutations and systematically characterized the susceptibility of these clones to both first- and second-generation INSTIs. METHODS: The infectious clones were tested for their infectivity and susceptibility to INSTIs in a single-cycle assay using TZM-bl cells. RESULTS: A single mutation of thymidine (T) at the fifth position (GGG GTG) in the G-tract of the 3'-PPT had no effect on INSTI resistance. A double mutation, cytidine (C) or 'T' at the second position and 'T' at the fifth position (GCG GTG and GTG GTG), increased resistance to INSTIs, with the appearance of a plateau in the maximal percentage inhibition (MPI) of the dose-response curves, consistent with a non-competitive mechanism of inhibition. CONCLUSIONS: Mutations at the second and fifth positions in the G-tract of the 3'-PPT may result in complex resistance mechanism(s), rather than simply affecting INSTI binding at the IN active site.
Authors: John G Julias; Mary Jane McWilliams; Stefan G Sarafianos; W Gregory Alvord; Eddy Arnold; Stephen H Hughes Journal: J Virol Date: 2004-12 Impact factor: 5.103
Authors: Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara Journal: Antimicrob Agents Chemother Date: 2010-11-29 Impact factor: 5.191
Authors: Atsuko Hachiya; Aaron B Reeve; Bruno Marchand; Eleftherios Michailidis; Yee Tsuey Ong; Karen A Kirby; Maxwell D Leslie; Shinichi Oka; Eiichi N Kodama; Lisa C Rohan; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos Journal: Antimicrob Agents Chemother Date: 2013-06-24 Impact factor: 5.191
Authors: Ingeborg E A Wijting; Cynthia Lungu; Bart J A Rijnders; Marchina E van der Ende; Hanh T Pham; Thibault Mesplede; Suzan D Pas; Jolanda J C Voermans; Rob Schuurman; David A M C van de Vijver; Patrick H M Boers; Rob A Gruters; Charles A B Boucher; Jeroen J A van Kampen Journal: J Infect Dis Date: 2018-07-24 Impact factor: 5.226
Authors: Xiaowei Jiang; Felix Feyertag; Conor J Meehan; Grace P McCormack; Simon A Travers; Charles Craig; Mike Westby; Marilyn Lewis; David L Robertson Journal: J Virol Date: 2015-09-02 Impact factor: 5.103